Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
Known as fam-trastuzumab deruxtecan but marketed under the brand name Enhertu, it is meant to treat advanced breast cancer that is HR-positive and HER2-low or ultralow, which has not improved ...
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback